Working... Menu
Trial record 1 of 1 for:    NCT02089724
Previous Study | Return to List | Next Study

Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease (LOVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02089724
Recruitment Status : Unknown
Verified October 2016 by Dr Cohen Aubart, Groupe Hospitalier Pitie-Salpetriere.
Recruitment status was:  Recruiting
First Posted : March 18, 2014
Last Update Posted : October 28, 2016
Memorial Sloan Kettering Cancer Center
Information provided by (Responsible Party):
Dr Cohen Aubart, Groupe Hospitalier Pitie-Salpetriere